143 related articles for article (PubMed ID: 1910089)
1. Design and synthesis of HIV protease inhibitors. Variations of the carboxy terminus of the HIV protease inhibitor L-682,679.
deSolms SJ; Giuliani EA; Guare JP; Vacca JP; Sanders WM; Graham SL; Wiggins JM; Darke PL; Sigal IS; Zugay JA
J Med Chem; 1991 Sep; 34(9):2852-7. PubMed ID: 1910089
[TBL] [Abstract][Full Text] [Related]
2. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
Dis Markers; 1990; 8(3):162-3. PubMed ID: 2125537
[No Abstract] [Full Text] [Related]
3. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
[TBL] [Abstract][Full Text] [Related]
4. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
Dreyer GB; Lambert DM; Meek TD; Carr TJ; Tomaszek TA; Fernandez AV; Bartus H; Cacciavillani E; Hassell AM; Minnich M
Biochemistry; 1992 Jul; 31(29):6646-59. PubMed ID: 1637805
[TBL] [Abstract][Full Text] [Related]
6. Rapid detection of HIV-1 in clinical samples by co-culture with heat-shocked cells.
Re MC; Furlini G; La Placa M
J Virol Methods; 1989 Dec; 26(3):313-7. PubMed ID: 2482842
[TBL] [Abstract][Full Text] [Related]
7. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
McQuade TJ; Tomasselli AG; Liu L; Karacostas V; Moss B; Sawyer TK; Heinrikson RL; Tarpley WG
Science; 1990 Jan; 247(4941):454-6. PubMed ID: 2405486
[TBL] [Abstract][Full Text] [Related]
8. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.
Ashorn P; McQuade TJ; Thaisrivongs S; Tomasselli AG; Tarpley WG; Moss B
Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7472-6. PubMed ID: 2217178
[TBL] [Abstract][Full Text] [Related]
9. Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease.
Serio D; Singh SP; Cartas MA; Weber IT; Harrison RW; Louis JM; Srinivasan A
Protein Eng; 2000 Jun; 13(6):431-6. PubMed ID: 10877854
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 infection of endothelial cells in vitro.
Re MC; Furlini G; Cenacchi G; Preda P; La Placa M
Microbiologica; 1991 Apr; 14(2):149-52. PubMed ID: 1713288
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
Meek TD; Lambert DM; Dreyer GB; Carr TJ; Tomaszek TA; Moore ML; Strickler JE; Debouck C; Hyland LJ; Matthews TJ
Nature; 1990 Jan; 343(6253):90-2. PubMed ID: 1688646
[TBL] [Abstract][Full Text] [Related]
12. Infection of human thymic lymphocytes by HIV-1.
Tremblay M; Numazaki K; Goldman H; Wainberg MA
J Acquir Immune Defic Syndr (1988); 1990; 3(4):356-60. PubMed ID: 1690286
[TBL] [Abstract][Full Text] [Related]
13. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
Kageyama S; Mimoto T; Murakawa Y; Nomizu M; Ford H; Shirasaka T; Gulnik S; Erickson J; Takada K; Hayashi H
Antimicrob Agents Chemother; 1993 Apr; 37(4):810-7. PubMed ID: 8494379
[TBL] [Abstract][Full Text] [Related]
14. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
[TBL] [Abstract][Full Text] [Related]
15. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
Davis DA; Brown CA; Singer KE; Wang V; Kaufman J; Stahl SJ; Wingfield P; Maeda K; Harada S; Yoshimura K; Kosalaraksa P; Mitsuya H; Yarchoan R
Antiviral Res; 2006 Nov; 72(2):89-99. PubMed ID: 16687179
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 gag proteins in virions and in infected cell fractions.
Sharova NK; Grigor'ev VB; Bukrinskaya AG
Biomed Sci; 1991; 2(3):279-84. PubMed ID: 1751761
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of human immunodeficiency virus 1 replication in monocytes by 1,25-dihydroxycholecalciferol.
Skolnik PR; Jahn B; Wang MZ; Rota TR; Hirsch MS; Krane SM
Proc Natl Acad Sci U S A; 1991 Aug; 88(15):6632-6. PubMed ID: 1650477
[TBL] [Abstract][Full Text] [Related]
20. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
